###begin article-title 0
###xml 13 14 13 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Cytosolic PLA2 is required for CTL-mediated immunopathology of celiac disease via NKG2D and IL-15
###end article-title 0
###begin p 1
F. Tang and Z. Chen contributed equally to this paper.
###end p 1
###begin p 2
###xml 265 266 265 266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 272 273 272 273 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 400 401 400 401 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 652 653 652 653 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 694 695 694 695 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 806 807 806 807 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 741 749 <span type="species:ncbi:9606">patients</span>
IL-15 and NKG2D promote autoimmunity and celiac disease by arming cytotoxic T lymphocytes (CTLs) to cause tissue destruction. However, the downstream signaling events underlying these functional properties remain unclear. Here, we identify cytosolic phospholipase A2 (cPLA2) as a central molecule in NKG2D-mediated cytolysis in CTLs. Furthermore, we report that NKG2D induces, upon recognition of MIC+ target cells, the release of arachidonic acid (AA) by CTLs to promote tissue inflammation in association with target killing. Interestingly, IL-15, which licenses NKG2D-mediated lymphokine killer activity in CTLs, cooperates with NKG2D to induce cPLA2 activation and AA release. Finally, cPLA2 activation in intraepithelial CTLs of celiac patients provides an in vivo pathophysiological dimension to cPLA2 activation in CTLs. These results reveal an unrecognized link between NKG2D and tissue inflammation, which may underlie the emerging role of NKG2D in various immunopathological conditions and define new therapeutic targets.
###end p 2
###begin p 3
###xml 57 58 57 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 205 206 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib3">3</xref>
###xml 293 294 293 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib4">4</xref>
###xml 296 297 296 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib5">5</xref>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 366 367 366 367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib7">7</xref>
###xml 392 393 392 393 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib9">9</xref>
###xml 502 503 502 503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 505 507 505 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib12">12</xref>
###xml 613 615 613 615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 792 793 792 793 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 1055 1056 1055 1056 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 1058 1060 1058 1060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 1062 1064 1062 1064 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib14">14</xref>
###xml 1404 1406 1404 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 45 50 <span type="species:ncbi:9606">human</span>
###xml 404 409 <span type="species:ncbi:10090">mouse</span>
###xml 453 459 <span type="species:ncbi:9606">humans</span>
###xml 933 938 <span type="species:ncbi:9606">human</span>
NKG2D is a NK cell receptor expressed by all human CTLs (1) that recognizes MHC class I-related chain (MIC) and UL-16-binding protein (ULPB) molecules expressed on stressed and transformed target cells (1-3). NKG2D has been implicated in antitumor immunity mediated by both NK cells and CTLs (4, 5) and in T cell-mediated immune disorders such as celiac disease (6, 7), rheumatoid arthritis (8), and NOD mouse model for juvenile type 1 diabetes (9). In humans, NKG2D associates exclusively with DAP10 (6, 10-12), an adaptor with a YINM cytoplasmic tail motif that activates phosphatidylinositol 3-kinase (PI3-K) (10), but not the syk/ZAP-70 kinase family. Because of these similarities with the CD28 signaling pathway, NKG2D-DAP10 was initially thought to function mainly as a co-stimulator (1) and to play a role in autoimmunity by promoting activation of autoreactive T cells. However, several studies indicate that NKG2D-DAP10 in human can also mediate cytolysis independently of TCR engagement in effector CTLs exposed to IL-15 or high doses of IL-2 (6, 13, 14). This layer of effector T cell regulation by NKG2D at the level of cytolysis may serve to effectively and rapidly eliminate infected or transformed target tissue cells independently of antigen specificity, and may participate in aberrant tissue destruction in diseases in which IL-15 expression is dysregulated (for review see reference [15]).
###end p 3
###begin p 4
###xml 172 173 172 173 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 231 233 231 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib16">16</xref>
###xml 234 236 234 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib18">18</xref>
###xml 256 257 256 257 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 409 410 409 410 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 436 438 436 438 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib20">20</xref>
###xml 462 463 462 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 530 532 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib21">21</xref>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib23">23</xref>
###xml 578 580 578 580 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib24">24</xref>
###xml 581 583 581 583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib27">27</xref>
###xml 736 737 736 737 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 808 811 808 811 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">505</sup>
###xml 828 830 828 830 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 949 950 949 950 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 1034 1035 1034 1035 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
The downstream co-stimulatory and cytolytic signaling pathways recruited by NKG2D in CTLs remain incompletely characterized. Intriguingly, several studies suggest that cPLA2 may be involved in inflammatory and autoimmune diseases (16-18). However, how cPLA2 drives immunopathological processes and whether it involves CTLs is poorly understood. Interestingly, several reports point to a potential role of cPLA2 in T cell proliferation (19, 20). Furthermore, cPLA2 was shown to be involved in granule exocytosis by neuronal cells (21, 22), hormonal cells (23), and granulocytes (24-27), suggesting that it might also be implicated in granular release occurring in the context of cytolysis and cytokine secretion in T cells. Finally, cPLA2 activation by surface receptors is dependent on phosphorylation at Ser505 by MAP kinases (28), and NKG2D induces c-Jun N-terminal kinase (JNK) and extracellular signal-regulated kinase (ERK) activation in CTLs (6). Together, these observations prompted us to examine a potential link between cPLA2 and NKG2D effector function in CTLs and its relevance in celiac disease.
###end p 4
###begin title 5
RESULTS
###end title 5
###begin title 6
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
cPLA2 plays a critical role in direct NKG2D-mediated cytolysis
###end title 6
###begin p 7
###xml 166 167 166 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 239 240 239 240 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 432 433 432 433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 871 872 871 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 670 678 <span type="species:ncbi:9606">patients</span>
NKG2D is licensed to mediate cytolysis independently of TCR activation in CTLs when they are in an effector stage and in the presence of IL-15 or high doses of IL-2 (6). Importantly, under these conditions it is possible to assess how cPLA2 affects NKG2D effector functions independently from other receptors. To determine that our findings were not restricted to a particular subset of effector CTLs, we analyzed the effect of cPLA2 inhibition in a variety of effector CTLs. Specifically, we studied freshly isolated effector intestinal intraepithelial CTLs (IE-CTLs) that were prestimulated in vitro with IL-15, normal IE-CTL clones, IE-CTL clones derived from celiac patients, peripheral blood effector CTL (PB-CTL) clones, and the leukemia TALL-104 CD8 T cell line. This latter cell line was previously used as a model to study the NKG2D cytolytic signaling pathway (6). All clones and cell lines were grown in the presence of a high concentration of IL-2, which is known to substitute for IL-15.
###end p 7
###begin p 8
###xml 8 9 8 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 109 117 109 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 234 242 234 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
###xml 378 379 378 379 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 399 407 399 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 A</xref>
The cPLA2 inhibitor AACOCF3 (CF3) impaired NKG2D-mediated cytolysis in antibody-redirected cytolytic assays (Fig. 1 A, left). Importantly, this finding could be extended to cytolytic assays using MIC-transfected C1R cells as targets (Fig. 1 A, right). Furthermore, arachidonic acid (AA) significantly restored cytolysis, strongly arguing against a nonspecific effect of the cPLA2 inhibitor AACOCF3 (Fig. 1 A, right). Finally, AACOCF3 and AA had a dose-dependent effect on NKG2D-mediated cytolysis in freshly isolated IE-CTLs (Fig. S1, available at ).
###end p 8
###begin p 9
###xml 39 40 39 40 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 51 0 51 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NKG2D-mediated cytolysis in CTL is cPLA<sub>2</sub> dependent.</bold>
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 737 738 731 732 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1166 1167 1148 1149 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1323 1324 1305 1306 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1418 1419 1400 1401 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1454 1455 1436 1437 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1737 1738 1719 1720 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1818 1830 1800 1812 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Right panel:</italic>
###xml 1835 1836 1817 1818 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1930 1932 1912 1914 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 1951 1952 1929 1930 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1975 1976 1953 1954 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2300 2301 2276 2277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2348 2349 2324 2325 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2525 2526 2497 2498 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2640 2641 2612 2613 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2693 2694 2665 2666 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2724 2725 2696 2697 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 2777 2778 2749 2750 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2911 2912 2883 2884 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 3092 3093 3064 3065 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 3117 3118 3089 3090 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">-</sup>
###xml 3267 3268 3239 3240 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
NKG2D-mediated cytolysis in CTL is cPLA2 dependent. (A) cPLA2 inhibition by the pharmacological inhibitor AACOCF3 (CF3) blocks NKG2D-mediated cytotoxicity. Fresh IE-CTL prestimulated with IL-15 for 48 h, celiac IE-CTL clones, PB-CTL clones, and TALL-104 leukemia CTLs were pretreated for 30 min with vehicle control or CF3 before the cytolysis assay. Depending on the nature of the CTLs studied, distinct E/T ratios were used to achieve similar levels of specific lysis (50:1 for fresh IE-CTLs and PB-CTLs, 15:1 for celiac IE-CTLs, and 5:1 for TALL-104 leukemia CTLs). Data are means +/- SD of three independent experiments for each cell line. P values reported are from a Tukey-adjusted pairwise comparison. (left) Cytolysis of FcgammaR+ P815 cells was significantly blocked by 20 microM CF3 in the presence of anti-NKG2D, but not anti-CD3, antibody. (right) Cytolysis of C1R/MIC transfectants was blocked upon pretreatment of CTLs with 20 microM CF3 and restored when 100 microM AA was added 1 h after the beginning of the cytolysis assay. Importantly, CF3 did not affect the level of intracellular granzyme and perforin expression (Fig. S2). (B) Knockdown of cPLA2 in TALL-104 CTLs significantly impairs NKG2D-mediated cytolysis, but not TCR-mediated cytolysis under optimal conditions of stimulation. Untransfected cPLA2 and control siRNA-transfected TALL-104 CTLs were studied 72 h after transfection. (left) cPLA2 siRNA significantly decreases cPLA2 expression without affecting JNK and ERK activation. Untransfected and transfected TALL-104 were cultured for 72 h, serum-starved overnight, and stimulated for 5 min (p-ERK) or 15 min (p-JNK), respectively, with anti-NKG2D. Cell lysates were analyzed by Western blot with anti-cPLA2, then stripped and blotted with anti-phospho-ERK (p-ERK) or -JNK (p-JNK) mAbs. Right panel: cPLA2 siRNA inhibited significantly NKG2D-mediated cytolysis in a redirected cytolytic assay using 51Cr-labeled FcgammaR+ P815 targets. (C) cPLA2 knocked down in PB-CTLs blocked the release of cytolytic granule. An esterase assay was performed 36 h after transfection. Data are means +/- SD of six experimental points from two independent experiments. P values are from a Tukey-adjusted pairwise comparison. (D) AA reconstitutes NKG2D cytolytic function against C1R/MIC+ target cells in TALL-104 transfected with cPLA2 siRNA. Rescue experiments were performed by adding 50 microM of AA or a control polyunsaturated fatty acid LA after 1 h co-culture with target cells. (left) Knock-down of cPLA2 did not affect 5-LO expression, whereas 5-LO siRNA decreased significantly 5-LO expression without affecting cPLA2 expression. Cells were sorted into transfected (GFP+) and untransfected cells (GFP-) cell populations 24 h after transfection with cPLA2 siRNA, control siRNA or 5-LO siRNA in addition to GFP plasmids. Cell lysates were analyzed 12 h later by Western blot with anti-cPLA2 antibody, then stripped and immunoblotted with anti-5-LO antibody. (middle) Cytolysis assays were performed 36 h after transfection at the indicated E:T ratios in transfected (GFP+) and untransfected (GFP-) cells. One representative experiment out of two independent experiments is shown. (right) Cells were cultured for 72 h after transfection with cPLA2 or control siRNA and cytolysis assays were performed in absence of cell sorting on the total cell population. The transfection efficiency, determined by GFP expression, was approximately60%. Data are means +/- SD of six experimental points from two independent experiments. P values are from a Tukey-adjusted pairwise comparison.
###end p 9
###begin p 10
###xml 43 44 43 44 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 98 99 98 99 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 132 147 132 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, B and C</xref>
###xml 162 170 162 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 189 190 189 190 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 235 236 235 236 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 269 270 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 360 368 360 368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 415 423 415 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 450 451 450 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 644 645 644 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 778 786 778 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 917 918 917 918 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 938 946 938 946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 B</xref>
###xml 1007 1008 1007 1008 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1026 1034 1026 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 1066 1074 1066 1074 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 1177 1185 1177 1185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
###xml 1273 1288 1273 1288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1, B and D</xref>
###xml 1326 1327 1326 1327 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1347 1348 1347 1348 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1369 1377 1369 1377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 D</xref>
To further assess the critical role of cPLA2 in NKG2D-mediated cytolysis and granule release, cPLA2 was "knocked down" in TALL-104 (Fig. 1, B and C) and PB-CTLs (Fig. 1 B, right) using cPLA2 small interfering (si)RNA. Importantly, cPLA2 siRNA specifically targeted cPLA2 expression, as it affected neither ERK nor JNK expression (not depicted) and activation (Fig. 1 B, left), nor 5-lipoxygenase (5-LO) expression (Fig. 1 C, left). The effect of cPLA2 knock down on NKG2D-mediated cytolysis was assessed in two ways. First, in redirected cytolytic assays, as expected, NKG2D-mediated cytolysis was inhibited by up to 50% in the presence of cPLA2 siRNA, but not control siRNA. In contrast, TCR-mediated cytolysis remained essentially intact for this level of specific cytolysis (Fig. 1 B, middle). The level of inhibition observed for NKG2D-mediated cytolysis was highly significant considering that some residual cPLA2 could be detected (Fig. 1 B, left). Second, similar results were obtained when using MIC+C1R target cells (Fig. 1 D). Importantly, addition of AA (Fig. 1 D), but not a control polyunsaturated fatty acid, linoleic acid (LA), rescued NKG2D-mediated cytolysis (Fig. 1 D, right). The assays were performed either with global unsorted siRNA-transfected CTLs (Fig. 1, B and D, right), or with CTLs sorted into GFP+-transfected and GFP--untransfected CTLs (Fig. 1 D, middle).
###end p 10
###begin p 11
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 317 318 317 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 355 356 355 356 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 367 375 367 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Fig. 1 C</xref>
###xml 520 521 520 521 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 656 657 656 657 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Having shown that cPLA2 played a role in NKG2D-mediated cytolysis, we wanted to more specifically demonstrate its role in the release of cytolytic granules. We previously reported, that ligation of NKG2D receptors expressed on CTLs with monoclonal anti-NKG2D mAb triggered granule release using a BLT esterase assay (6). As anticipated, knock down of cPLA2 by siRNA (Fig. 1 C) blocked degranulation. Similar results were obtained in the presence of the pharmacological inhibitor CF3 (unpublished data). Importantly, cPLA2 inhibition did not affect the level of granzyme and perforin expression in CTLs (Fig. S2, available at ), further suggesting that cPLA2 plays a role in NKG2D-mediated degranulation.
###end p 11
###begin p 12
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 115 122 115 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figs. 1</xref>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">2</xref>
Interestingly, cPLA2 inhibition by AACOCF3 or knock down by siRNA affected only marginally TCR-mediated cytolysis (Figs. 1 and 2).
###end p 12
###begin p 13
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 75 0 75 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cPLA<sub>2</sub> activation is necessary for NKG2D cytolytic co-stimulatory functions.</bold>
###xml 94 95 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 576 578 576 578 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 593 594 593 594 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
cPLA2 activation is necessary for NKG2D cytolytic co-stimulatory functions. Inhibition of cPLA2 blocks NKG2D augmentation of cytolytic T cell functions and AA reverses this blockage. Co-stimulation of cytolytic T cell functions by NKG2D was studied using three different PB-CTL clones (#411, #414, and #348) that were generated and cultured with low IL-2 (5 U/ml), in which NKG2D does not mediate direct cytolysis. Representative experiments of clone 411(top) and 414 (middle) are shown. PB-CTLs were pretreated with vehicle or CF3. Redirected cytolysis was performed against 51Cr-labeled FcgR+ P815 targets (E/T ratio of 50:1) in the presence of anti-CD3 mAbs at the indicated concentration in combination with either anti-NKG2D mAbs or isotype control IgG1 at fixed concentration (1 microg/ml). (bottom) A rescue experiment was performed by adding AA to CF3-pretreated cells 1 h after co-culture with target cells. A summary of three independent experiments for an anti-CD3 mAb concentration of 12.5 ng/ml with means +/- SD is shown. P values are from a Tukey-adjusted pairwise comparison.
###end p 13
###begin p 14
###xml 47 48 47 48 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Altogether, these results demonstrate that cPLA2 and AA play a critical role in NKG2D-mediated, but not TCR-mediated, cytolytic granule exocytosis in effector CTLs.
###end p 14
###begin title 15
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
cPLA2 plays a critical role in NKG2D-mediated cytolytic co-stimulatory functions
###end title 15
###begin p 16
###xml 106 108 106 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 110 112 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 153 154 153 154 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 373 375 373 375 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib29">29</xref>
###xml 462 468 462 468 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 488 489 488 489 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 607 613 607 613 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
###xml 633 634 633 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 709 715 709 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig2">Fig. 2</xref>
NKG2D was shown to function as a co-stimulatory receptor that enhances TCR-dependent cytolytic responses (13, 29). We therefore investigated whether cPLA2 was also implicated in NKG2D cytolytic co-stimulatory functions. This study had to be performed in CTLs grown in medium with low IL-2, in which NKG2D was not licensed to mediate direct killing. As previously reported (29), NKG2D significantly increased TCR-mediated cytolysis in two distinct PB-CTL clones (Fig. 2). Importantly, cPLA2 inhibition prevented NKG2D enhancement of TCR-mediated cytolysis, and AA significantly rescued NKG2D co-stimulation (Fig. 2). In contrast, cPLA2 inhibition had little or no significant effect on TCR-mediated cytolysis (Fig. 2).
###end p 16
###begin p 17
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
In summary, these observations also support a role for cPLA2 in NKG2D cytolytic co-stimulatory functions.
###end p 17
###begin title 18
###xml 18 19 18 19 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
NKG2D induces cPLA2 activation and AA release in effector CTLs
###end title 18
###begin p 19
###xml 41 42 41 42 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 94 95 94 95 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 236 237 236 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib19">19</xref>
###xml 284 286 284 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib30">30</xref>
###xml 347 348 347 348 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 388 394 388 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 428 434 428 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 468 469 468 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 514 520 514 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 208 216 <span type="species:ncbi:9606">patients</span>
To establish a biochemical basis for cPLA2 functions in CTLs, we determined NKG2D-induced cPLA2 phosphorylation and AA release in several different CTL subsets, including in IE-CTL clones derived from celiac patients. Expression of cPLA2 in mature T cells has been controversial (19, 30). However, using Western blot analysis, we demonstrated cPLA2 expression in different effector CTLs (Fig. 3, left). Furthermore, as shown in Fig. 3, NKG2D cross-linking induced cPLA2 phosphorylation in a dose-dependent manner (Fig. 3, left).
###end p 19
###begin p 20
###xml 36 37 36 37 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 77 0 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">NKG2D and TCR engagement induce cPLA<sub>2</sub> phosphorylation and AA release in CTLs.</bold>
###xml 192 193 192 193 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 386 387 386 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 394 395 394 395 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 470 471 470 471 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 581 582 581 582 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 619 620 619 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 773 774 773 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 833 834 833 834 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
NKG2D and TCR engagement induce cPLA2 phosphorylation and AA release in CTLs. Celiac IE-CTL clone (A), PB-CTL clone (B), and TALL-104 CTLs (C) were studied. (left) Concentration-dependent cPLA2 phosphorylation upon NKG2D and TCR engagement. CTLs were serum starved for 16 h, and then stimulated for 15 min as indicated. Cell lysates were analyzed by Western blot using anti-phospho-cPLA2 (p-PLA2)-specific antibody. The membrane was stripped and reblotted with anti-cPLA2 antibody to assess equal loading. (right) AA release upon NKG2D and TCR engagement. CTLs were incubated with 3H-AA for 10 h, washed to remove free 3H-AA, and stimulated with the indicated antibody or isotype control for 1 h. Supernatants and cell pellets were separately harvested. Total and released 3H-AA were measured to determine the percentage of released 3H-AA. Mean value of triplicates was used for each of the three experiments. Data are means +/- SD of three independent experiments. P values are from a Tukey-adjusted pairwise comparison.
###end p 20
###begin p 21
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 102 103 102 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 112 113 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 217 218 217 218 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 267 268 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
To further assess the ability of NKG2D to activate cPLA2, we studied perinuclear translocation of cPLA2 and cPLA2 activity in IE- and PB-CTLs. As anticipated, NKG2D engagement induced perinuclear translocation of cPLA2 (Fig. S3 A, available at ) and up-regulated cPLA2 activity (Fig. S3 B), which were blocked in the presence of the pharmacological inhibitor CF3 (Fig. S3).
###end p 21
###begin p 22
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 167 168 164 165 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 350 352 347 349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 407 408 404 405 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 439 440 436 437 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 452 453 442 443 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 626 627 616 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
To determine whether the capacity of NKG2D to induce cPLA2 phosphorylation in CTLs was dependent on their activation status, we sorted freshly purified resting CD8beta+ peripheral blood T cells that were used either immediately for biochemical studies or to establish a short-term effector CTL line by allogenic stimulation, as previously described (31). Interestingly, NKG2D and IL-15 failed to induce cPLA2 phosphorylation in resting CD8+TCRalphabeta+ peripheral blood lymphocytes, but not in the short-term derived effector CTL line (Fig. S4, available at ). These findings are in accordance with previously reported data (6) showing that licensing of NKG2D by IL-15 to mediate cytolysis was restricted to CTLs in the effector stage.
###end p 22
###begin p 23
###xml 50 51 50 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 100 106 100 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig3">Fig. 3</xref>
###xml 205 206 205 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Finally, we investigated whether induction of cPLA2 phosphorylation was associated with AA release (Fig. 3, right). This was investigated under conditions of stimulation resulting in maximal levels of cPLA2 phosphorylation. TCR stimulation induced AA release. However, importantly, NKG2D could induce AA release independently of TCR engagement.
###end p 23
###begin p 24
###xml 66 67 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Collectively, these results demonstrate that NKG2D can induce cPLA2 activation and mediate AA release independently of TCR stimulation. This unexpected function of NKG2D suggests that in tissues expressing stress-induced ligands, CTLs could participate in the activation of granulocytes sensitive to the presence of AA.
###end p 24
###begin title 25
###xml 58 59 58 59 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
ERK and JNK regulate NKG2D-mediated cytolysis through cPLA2 activation in CTLs
###end title 25
###begin p 26
###xml 178 179 178 179 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 271 272 271 272 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 383 385 383 385 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 468 469 468 469 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Previous studies had shown that NKG2D activated ERK and JNK through distinct pathways and that both MAP kinases regulated NKG2D-mediated cytolysis in CTLs in an additive manner (6). However, how ERK and JNK played a role in cytolysis remained elusive. Interestingly, cPLA2 activation by surface receptors was shown to be dependent on MAP kinase activation (for review see reference [28]). This prompted us to investigate whether there was a link between ERK, JNK, cPLA2 activation, and NKG2D-mediated cytolysis.
###end p 26
###begin p 27
###xml 53 54 53 54 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 111 112 111 112 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 213 221 213 221 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 267 268 267 268 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
We first determined the kinetic of ERK, JNK, and cPLA2 phosphorylation upon NKG2D stimulation. The peak of cPLA2 phosphorylation occurred at 10-15 min after ERK and concomitant with JNKK1 and JNK phosphorylation (Fig. 4 A, top left). These results suggested that cPLA2 phosphorylation was downstream of ERK and JNK.
###end p 27
###begin p 28
###xml 24 25 24 25 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ERK and JNK control cPLA<sub>2</sub> activation and NKG2D-mediated cytolysis.</bold>
###xml 101 102 101 102 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 475 476 475 476 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 569 570 569 570 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 775 776 771 772 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 844 845 840 841 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 906 907 902 903 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1238 1240 1234 1236 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">51</sup>
###xml 1384 1385 1374 1375 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1578 1579 1568 1569 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1649 1650 1639 1640 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1887 1888 1877 1878 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2059 2060 2045 2046 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2266 2267 2248 2249 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2470 2471 2452 2453 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2755 2756 2737 2738 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2764 2765 2746 2747 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 2791 2792 2773 2774 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2999 3000 2981 2982 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 3078 3079 3060 3061 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 3111 3112 3093 3094 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 3215 3216 3197 3198 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 3333 3334 3315 3316 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 3410 3411 3392 3393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
ERK and JNK control cPLA2 activation and NKG2D-mediated cytolysis. (A) JNK and ERK both regulate cPLA2 phosphorylation and cytolysis. Results shown were obtained with TALL-104 CTLs. Similar results were obtained with IE-CTLs. (top left) Phosphorylation time course. TALL-104 CTLs were serum-starved for 16 h before stimulation with anti-NKG2D antibodies for the indicated time. Cell lysates were subjected to Western blot analysis by anti-phospho-ERK, -JNKK1, -JNK, and -cPLA2-specific antibodies. (bottom left) ERK and JNK inhibitors block, in an additive manner, cPLA2 phosphorylation. TALL-104 CTLs were pretreated with vehicle or suboptimal doses (10 microM) of specific kinase inhibitors. PD 98059 (PD) and SP600125 (SP) are MEK1/2 and JNK inhibitors, respectively. cPLA2 phosphorylation was determined by immunoblot with anti-phospho cPLA2 after 15 min of stimulation with anti-NKG2D mAbs. Total cPLA2 is shown as loading control. (right) AA significantly restored NKG2D-mediated cytolysis against C1R/MIC transfectants upon JNK, but not ERK, inhibition. TALL-104 CTLs were pretreated with vehicle and inhibitors as indicated in the top right graph. The rescue assay was done by addition of AA 1 h after co-culture of TALL-104 with 51Cr-labeled C1R/MIC transfectants. Data are means +/- SD of three independent cytolytic assays. (B) The Vav-->JNKK1/2-->JNK pathway controls cPLA2 phosphorylation. Phosphorylation experiments were performed on cells starved overnight and stimulated for the indicated time with anti-NKG2D antibodies. Western blots for phospho-JNK and -cPLA2 were performed on total cell lysates using anti-phospho-JNK and -cPLA2 antibodies. Vav phosphorylation was evaluated after immunoprecipitation with anti-Vav1 mAb and immunoblotting with anti-phosphotyrosine mAb. Equal loading for total lysates and for Vav 1 immunoprecipitation were assessed using anti-cPLA2 and -Vav antibody, respectively. (top left) Time course of anti-NKG2D-induced Vav phosphorylation. (top right) Dominant-negative Vav-1 (Vav 1-DeltaC) blocked JNK and cPLA2 activation. TALL-104 CTLs were transfected with control vector and Vav-DeltaC and cultured for 48 h. Cells were then analyzed by Western blot as indicated. (bottom left) Dominant-negative JNKK2 blocks cPLA2 phosphorylation. TALL-104 CTLs transfected with control vector and dominant-negative JNKK2(KM) were cultured for 48h and analyzed by Western blot. (bottom right) Constitutive JNK activation induced cPLA2 phosphorylation. TALL-104 CTLs were transfected with JNKK2-JNK1 (which encodes a constitutively active form of JNK) or with JNKK2(KM)-JNK1 (which encodes a kinase-deficient mutant), in addition to GFP plasmids. After 40 h of transfection, cells were sorted by flow cytometry into GFP+ and GFP- cells. Presence of p-cPLA2 was evaluated by immunoblot in the absence of NKG2D stimulation. NKG2D-stimulated and nonstimulated TALL-104 CTLs, transfected with a control vector, served as positive and negative control for JNK and cPLA2 phosphorylation. Equal loading was assessed by immunoblotting with total cPLA2. (C) ERK pathway regulates cPLA2 phosphorylation. Dominant-negative and overexpression experiments were performed as in B. ERK and cPLA2 phosphorylation were determined by Western blot. (left) Dominant-negative MEK-1 (MEK[2A]) significantly blocked cPLA2 phosphorylation. (right) Constitutively active MEK-1 (MEK[2E]) induced cPLA2 phosphorylation in the absence of NKG2D stimulation.
###end p 28
###begin p 29
###xml 55 56 55 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 203 204 203 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 222 230 222 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 520 521 520 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 641 649 641 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
To further evaluate the function of JNK and ERK in cPLA2 activation and NKG2D-mediated cytolysis, we performed studies with pharmacological inhibitors targeting specific MAP kinases. As anticipated, cPLA2 phosphorylation (Fig. 4 A, bottom left) and AA release (not depicted) were blocked in an additive manner upon ERK (PD98059) and JNK (SP600125) inhibition. In contrast, the p38 inhibitor SB 203580 had no effect (unpublished data), a result that is in agreement with its lack of function in NKG2D-mediated cytolysis (6). Finally, addition of AA reversed JNK inhibition, more significantly than ERK inhibition of NKG2D-mediated cytolysis (Fig. 4 A, right).
###end p 29
###begin p 30
###xml 112 113 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 268 270 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib32">32</xref>
###xml 361 363 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 365 367 363 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 553 568 551 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4, A and B</xref>
###xml 631 633 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 661 662 659 660 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 709 717 707 715 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 772 773 770 771 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 967 968 965 966 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1008 1016 1006 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
###xml 1146 1148 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 1181 1182 1179 1180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1231 1239 1229 1237 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 B</xref>
We next dissected the signaling pathway leading to JNK activation and further assessed its critical role in cPLA2 activation using a dominant-negative and overexpression approach. Vav1, which regulates JNK activation through a Rho/Rac1-->MAPK kinase kinase 1 pathway (32), was also reported to play an essential role in the NKG2D cytolytic pathway in NK cells (33, 34). These observations suggested that Vav1 could control JNK activation. In agreement, our kinetic analysis indicated that Vav1 activation preceded JNKK1 and JNK phosphorylation (compare Fig. 4, A and B, top left). In addition, a dominant-negative of Vav1, Vav1-C (33), blocked both JNK and cPLA2 activation after NKG2D cross-linking in CTLs (Fig. 4 B, top right). To further assess the role of JNK in cPLA2 phosphorylation, TALL-104 CTLs were transfected with a dominant-negative JNKK2, which was shown to prevent JNK activation. As anticipated, blocking JNK activation resulted in inhibition of cPLA2 phosphorylation upon NKG2D engagement (Fig. 4 B, bottom left). Conversely, simple overexpression of constitutive active JNK (JNKK2-JNK1), but not inactive JNK (JNKK2[KM]-JNK1) (35), induced similar levels of cPLA2 phosphorylation than NKG2D stimulation in CTLs (Fig. 4 B, bottom right).
###end p 30
###begin p 31
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 110 116 110 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7</xref>
###xml 166 167 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 266 268 266 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 270 272 270 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 329 330 329 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 348 356 348 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
###xml 427 429 427 429 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 431 433 431 433 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 448 449 448 449 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 467 475 467 475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 C</xref>
Finally, because the upstream events leading to ERK activation were defined by a previous study (6) (see also Fig. 7), we focused on assessing the role of ERK in cPLA2 activation. As predicted by the pharmacological studies, the dominant-negative of MEK-1 (MEK-2A) (36, 37), which is located upstream of ERK, blocked ERK and cPLA2 phosphorylation (Fig. 4 C, left), whereas overexpression of constitutive active MEK-1 (MEK-2E) (36, 37), induced cPLA2 phosphorylation (Fig. 4 C, right).
###end p 31
###begin p 32
###xml 116 117 116 117 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Altogether, these observations suggest that Vav is upstream of JNK, and that JNK and ERK control NKG2D-mediated cPLA2 activation in CTLs in an independent and additive manner.
###end p 32
###begin title 33
###xml 93 94 93 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
IL-15 arms NKG2D to mediate cytolysis and AA release in primary IE-CTLs by up-regulating cPLA2 expression and activation
###end title 33
###begin p 34
###xml 184 185 184 185 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 288 289 288 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 431 432 431 432 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 507 508 507 508 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 598 599 598 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 601 603 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 619 620 619 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 638 646 638 646 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 709 717 709 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 729 737 729 737 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig4">Fig. 4 A</xref>
###xml 763 764 763 764 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 860 868 860 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 A</xref>
###xml 933 934 933 934 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 963 971 963 971 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 B</xref>
###xml 1006 1014 1006 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 B</xref>
###xml 1028 1029 1028 1029 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1178 1179 1178 1179 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1255 1270 1255 1270 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5, C and D</xref>
###xml 1289 1290 1289 1290 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1314 1315 1314 1315 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1326 1334 1326 1334 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 C</xref>
###xml 1355 1363 1355 1363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 D</xref>
###xml 1408 1416 1408 1416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 D</xref>
We had previously demonstrated that IL-15 or high levels of IL-2 (which can substitute for IL-15) licensed NKG2D to mediate cytolysis independently of TCR activation in effector CTLs (6, 13). Furthermore, we showed that IE-CTLs exposed in vivo to IL-15 in active celiac disease killed MIC+ target cells (6). Here, we investigated whether the licensing of NKG2D to mediated direct cytolysis in freshly purified IE-CTLs involved cPLA2 activation by IL-15. We first determined whether IL-15 could activate cPLA2. Interestingly, IL-15 induced not only ERK and JNK phosphorylation, as previously shown (6, 38), but also cPLA2 phosphorylation (Fig. 5 A, left). The time course was similar to that of NKG2D (compare Fig. 5 A, left, and Fig. 4 A, left). In addition, cPLA2 expression was increased in primary IE-CTLs stimulated for 48 h with IL-15, but not with IL-7 (Fig. 5 A, right). Furthermore, IL-15 synergized with NKG2D to induce cPLA2 phosphorylation in a dose- (Fig. 5 B, left) and time-dependent manner (Fig. 5 B, right). cPLA2 activity was significantly up-regulated only in freshly isolated IE-CTLs that were prestimulated with IL-15 for 48 h. Importantly, induction of cPLA2 activity paralleled the ability of NKG2D to mediate degranulation (compare Fig. 5, C and D). Conversely, cPLA2 inhibition blocked cPLA2 activity (Fig. 5 C) and degranulation (Fig. 5 D), which was restored in the presence of AA (Fig. 5 D).
###end p 34
###begin p 35
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 107 0 107 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL-15 promotes NKG2D-mediated cytolytic degranulation, cPLA<sub>2</sub> activation, and AA release in primary IE-CTLs.</bold>
###xml 135 136 135 136 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 179 180 179 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 249 250 249 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 464 465 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 502 503 502 503 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 608 609 608 609 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 753 754 750 751 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1269 1270 1262 1263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
IL-15 promotes NKG2D-mediated cytolytic degranulation, cPLA2 activation, and AA release in primary IE-CTLs. (A) IL-15 up-regulates cPLA2 expression, and induces ERK, JNK, and cPLA2 activation in fresh IE-CTLs. (left) IL-15 induces ERK, JNK, and cPLA2 phosphorylation in a time-dependent manner. Fresh IE-CTLs were starved overnight and stimulated with 20 ng/ml IL-15 for indicated time periods. Cell lysates were immunoblotted with anti-p-ERK, -p-cPLA, and -p-cPLA2 antibodies. Total ERK and total cPLA2 are shown to assess equal loading. (right) Fresh IE-CTLs were cultured with IL-15 or IL-7 for 48 h. cPLA2 expression was determined by Western blot. Equal loading was assessed using an anti-CD3zeta mAb. (B) IL-15 synergizes with NKG2D to induce cPLA2 phosphorylation in a dose- (left) and time-dependent (right) manner. Fresh IE-CTLs (left) or TALL-104 CTLs (right) were stimulated with IL-15 alone, anti-NKG2D mAb alone, or IL-15 in combination with anti-NKG2D mAb for 15 min at the indicated concentration (left), or for the indicated time at saturating concentrations (4 microg/ml anti-NKG2D mAb and 20 ng/ml IL-15) (right). For each panel one out of 2 representative experiments is shown. (C and D) IL-15 stimulation plays a critical role in NKG2D-mediated cPLA2 activity (C) and cytolytic granule release (D) in primary IE-CTLs. Freshly purified IE-CTLs were cultured with or without IL-15 (20 ng/ml) for 24-48 h and pretreated for 30 min with vehicle control or CF3 before stimulation with anti-NKG2D mAb or IgG1 isotype control. Rescue experiments were performed by adding 50 microM of AA after 1 h of stimulation. Data are means +/- SD of six experimental points from two independent experiments. P values are from a Tukey-adjusted pairwise comparison. (E) IL-15 enhances NKG2D-mediated AA release. Fresh IE-CTLs were cultured with or without IL-15 (10 ng/ml) for 24 h and analyzed for AA release upon 1 h stimulation. (left) IE-CTLs were not stimulated (NS) or stimulated with plate-bound anti-NKG2D mAb (4 microg/ml). (right) IE-CTLs were stimulated with control EL-4 cells or MICA-transfected EL4 cells (MICA/EL-4) at a IE-CTLs to target cell ratio of 1:0.5. Data are means +/- SD of three independent experiments. P values are from a Tukey-adjusted pairwise comparison.
###end p 35
###begin p 36
###xml 100 108 100 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 E</xref>
###xml 358 366 358 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 E</xref>
###xml 410 418 410 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">Fig. 5 E</xref>
We next investigated whether NKG2D could induce AA release in primary effector IE-CTLs. As shown in Fig. 5 E, IL-15 and NKG2D independently induced AA release. The release was maximal when IE-CTLs were stimulated simultaneously by IL-15 and NKG2D. Importantly, AA release was also observed upon engagement of NKG2D by plate-coated monoclonal anti-NKG2D mAb (Fig. 5 E, left) and MIC-expressing EL4 fibroblasts (Fig. 5 E, right).
###end p 36
###begin p 37
###xml 146 147 146 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Altogether, these observations suggest that priming of the NKG2D cytolytic pathway by IL-15 in primary effector CTLs entails up-regulation of cPLA2 expression and activation. Furthermore, IL-15 and NKG2D can induce AA release.
###end p 37
###begin title 38
###xml 33 34 33 34 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 56 64 <span type="species:ncbi:9606">patients</span>
Expression of phosphorylated cPLA2 in IE-CTLs of celiac patients
###end title 38
###begin p 39
###xml 111 112 111 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 190 191 190 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 321 322 321 322 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
###xml 263 271 <span type="species:ncbi:9606">patients</span>
###xml 363 371 <span type="species:ncbi:9606">patients</span>
NKG2D and IL-15 were shown to play a critical role in celiac disease by licensing IE-CTLs to kill enterocytes (6). Furthermore, previous studies in active celiac patients reported that ERK (6) and JNK (38) phosphorylation were induced in IE-CTLs of active celiac patients. Together, these observations suggested that cPLA2 might be activated in IE-CTLs of celiac patients.
###end p 39
###begin p 40
###xml 109 110 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 201 202 201 202 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 244 245 244 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 286 287 284 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 318 326 314 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 562 564 558 560 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
###xml 566 568 562 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 584 585 580 581 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 676 684 672 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 814 815 810 811 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 834 842 830 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 B</xref>
###xml 1036 1038 1032 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib41">41</xref>
###xml 1091 1092 1087 1088 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1263 1264 1259 1260 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1356 1363 1352 1359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figs. 1</xref>
###xml 1368 1369 1364 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">5</xref>
###xml 234 242 <span type="species:ncbi:9606">patients</span>
###xml 1103 1111 <span type="species:ncbi:9606">patients</span>
In situ analysis of immunohistochemical staining with anti-CD3 antibody in combination with anti-phospho-cPLA2 antibody or control antibody revealed that the frequency of IE-CTL-expressing phospho-cPLA2 was highly increased in celiac patients (n = 6; 79 +/- 8%) compared with controls (n = 4; 13 +/- 4.6%; P = 0.001) (Fig. 6 B). In addition, to control for evaluation bias inherent to subjective morphological inspection and background staining, automatic image analysis was performed using the ACIS software (see Materials and methods) as previously described (39, 40). Specific cPLA2 staining appears in red when staining is above background threshold values after overlay (Fig. 6 A). Importantly, the automatic count confirmed the manual count by showing a similar significant increase in the percentage of cPLA2-positive IE-CTLs (Fig. 6 B). This result is even more striking in regard to the augmentation in the number of IE-CTLs in celiac disease, reaching classically up to 10 times the value of that observed in normal controls (41). The total number of IE-CTL-expressing phospho-cPLA2 in celiac patients can therefore be estimated to be 40-60-fold higher than in controls. This finding is particularly relevant in the context of our observations that cPLA2 plays a critical role in NKG2D cytolytic functions of celiac and IL-15-stimulated IE-CTLs (Figs. 1 and 5).
###end p 40
###begin p 41
###xml 12 13 12 13 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 0 62 0 62 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Phospho-cPLA<sub>2</sub> expression in IE-CTLs of active celiac patients.</bold>
###xml 158 159 158 159 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 335 336 335 336 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 406 407 406 407 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 445 446 445 446 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 504 505 504 505 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 589 590 589 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 816 817 816 817 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 963 964 963 964 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1069 1070 1069 1070 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1276 1277 1268 1269 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1277 1278 1269 1270 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1635 1636 1625 1626 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1636 1637 1626 1627 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
###xml 193 201 <span type="species:ncbi:9606">patients</span>
###xml 1157 1165 <span type="species:ncbi:9606">patients</span>
###xml 1387 1395 <span type="species:ncbi:9606">patients</span>
Phospho-cPLA2 expression in IE-CTLs of active celiac patients. (A) Representative examples of double staining immunohistochemistry of CD3 (brown)/phospho-cPLA2 (blue) in duodenal biopsies from patients with active celiac disease and controls (magnification x200). Intraepithelial lymphocytes were randomly selected from the pool of CD3+ cells and automatically numbered as shown. Expression of phospho-cPLA2 was measured within each outlined CD3+ IE-CTLs. In the left images, before overlay, phospho-cPLA2-positive appears in blue. After overlay, in the right images, specific phospho-cPLA2 staining as determined by threshold values is highlighted in red. (insets) IE-CTL #23 and #24 before and after applying the overlay tool. Note that double-positive IE-CTL #23 falls within the threshold values for phospho-cPLA2-positive staining and thus is covered with solid red in overlaid image. In contrast, IE-CTL #24 falls below the threshold values for phospho-cPLA2-positive staining and thus remains covered with white in overlaid image. Finally, increased phospho-cPLA2-positive epithelial cells (colored in red after overlay) are present in active celiac patients compared with controls. Bars: (a) 40 microm; (b) 10 microm. (B) A summary with mean percentage of phospho-cPLA2+ IE-CTLs +/- SD is presented after manual and automated count. For manual count, four control and six celiac patients were analyzed. For automated count, >100 IE-CTLs in two control and two celiac slides were analyzed. P value was determined with the exact Wilcoxon rank sum test. Note that manual and automated count give similar percentage of phospho-cPLA2+IE-CTLs.
###end p 41
###begin p 42
###xml 25 26 25 26 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 60 61 60 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib38">38</xref>
###xml 132 140 132 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6 A</xref>
###xml 269 271 269 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 122 130 <span type="species:ncbi:9606">patients</span>
Furthermore, phospho-cPLA2, similar to phospho-ERK and JNK (6, 38), was also highly up-regulated in enterocytes of celiac patients (Fig. 6 A), especially in the nuclear compartment (not depicted) where accumulation correlates with activation (for review see reference [28]).
###end p 42
###begin p 43
###xml 46 47 46 47 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 146 153 146 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig1">Figs. 1</xref>
###xml 158 159 158 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig5">5</xref>
###xml 171 172 171 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 212 213 212 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Altogether, these results illustrate that cPLA2 is activated in IE-CTLs of active celiac patients and support, in association with other present (Figs. 1 and 5) and past (6) observations, an in vivo role for cPLA2 in celiac disease pathogenesis.
###end p 43
###begin title 44
DISCUSSION
###end title 44
###begin p 45
###xml 262 263 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 400 401 400 401 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 570 576 570 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7</xref>
Our study establishes an unexpected connection between Il-15- and CTL-mediated immunopathology in celiac disease and inflammatory lipid biology. Our observations also suggest that NKG2D effector functions, particularly cytolysis, are critically regulated by cPLA2 in CTLs. Furthermore, we identify an unexpected role for Vav, JNK, and ERK in NKG2D-mediated cytolysis by showing that they mediate cPLA2 activation. Finally, our study suggests that NKG2D and IL-15 could contribute to tissue inflammation and granulocyte activation by promoting the release of AA in CTLs (Fig. 7).
###end p 45
###begin p 46
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Model of the NKG2D signaling pathway in CTLs.</bold>
###xml 133 135 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib60">60</xref>
###xml 279 280 275 276 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 458 459 454 455 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 555 556 545 546 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 588 589 572 573 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 659 661 643 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">62</xref>
###xml 663 665 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">63</xref>
###xml 667 669 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">67</xref>
###xml 689 690 673 674 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 825 826 809 810 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 870 871 854 855 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Model of the NKG2D signaling pathway in CTLs. The NKG2D cytolytic signaling pathway involves PLC-gamma2, Vav1, and PI3-K activation (60). How these upstream signaling events are interconnected in CTLs remains to be determined. NKG2D-mediated cytolysis requires activation of cPLA2 and AA release, suggesting that the level of calcium mobilization achieved upon NKG2D cross-linking is insufficient to allow membrane fusion events and exocytosis. Cytosolic PLA2 activation itself is mediated through two independent pathways, Vav-1-->JNKK1/2-->JNK1/2-->cPLA2 and PI3-K-->MEK1/2-->ERK-->cPLA2. It is likely that these pathways also promote granule polarization (62, 63, 67). In addition, cPLA2 activation is also required for NKG2D cytolytic co-stimulatory functions. Interestingly, IL-15, which licenses NKG2D killing in CTLs (6), enhances NKG2D-mediated JNK, ERK and cPLA2 phosphorylation, and AA release. Once released, AA can potentially be reincorporated into phospholipids, mediate the biosynthesis of eicosanoids and induce granulocyte activation.
###end p 46
###begin p 47
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib42">42</xref>
###xml 425 427 425 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib43">43</xref>
###xml 504 506 504 506 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">44</xref>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">45</xref>
###xml 614 616 614 616 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib46">46</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib10">10</xref>
###xml 805 807 805 807 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib34">34</xref>
###xml 809 811 809 811 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">47</xref>
###xml 887 889 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">48</xref>
###xml 890 892 890 892 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">52</xref>
###xml 1042 1044 1042 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib48">48</xref>
###xml 1045 1047 1045 1047 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">52</xref>
###xml 1069 1070 1069 1070 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1144 1146 1144 1146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib53">53</xref>
###xml 1239 1241 1239 1241 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib54">54</xref>
###xml 1243 1245 1243 1245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib55">55</xref>
###xml 1301 1303 1301 1303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib54">54</xref>
###xml 1419 1420 1419 1420 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1639 1640 1639 1640 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1869 1870 1869 1870 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1943 1944 1943 1944 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2164 2165 2164 2165 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2282 2284 2282 2284 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib47">47</xref>
###xml 2294 2295 2294 2295 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2319 2321 2319 2321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib56">56</xref>
###xml 2362 2363 2362 2363 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2540 2541 2540 2541 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 2572 2573 2572 2573 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2585 2586 2578 2579 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 2727 2729 2720 2722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib57">57</xref>
###xml 2833 2835 2826 2828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib58">58</xref>
###xml 2837 2839 2830 2832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib59">59</xref>
###xml 983 988 <span type="species:ncbi:9606">human</span>
###xml 1130 1133 <span type="species:ncbi:10116">rat</span>
###xml 1177 1182 <span type="species:ncbi:9606">human</span>
###xml 1520 1525 <span type="species:ncbi:9606">human</span>
###xml 1581 1586 <span type="species:ncbi:9606">human</span>
The molecular basis for exocytosis is a field of high investigation. It involves trafficking of granules to the plasma membrane and membrane fusion events. There is increasing evidence that exocytosis can be triggered, either under conditions of high-level calcium mobilization sufficient to activate snare-mediated membrane fusion (for review see references [42]), or under conditions of low levels of calcium mobilization (43) involving AA and its eicosanoids metabolites, which are known as fusogens (44). This latter mechanism is thought to play a role in neutrophil and neuroendocrine cell degranulation (45, 46). It may be particularly relevant for surface receptors that, similar to NKG2D, signal through an adaptor molecule lacking an ITAM motif (10), and induce relatively low levels of calcium (34, 47) (Fig. S5, available at ). Pharmacological studies performed in the 1980s (48-52) suggested that inflammatory lipid mediators may play a role in NK cell-mediated lysis in human and rodents without defining the receptors involved (48-52). More recently, cPLA2 was proposed to contribute to NKR-P1A-induced cytolysis in rat NK cells (53). However, recent findings in human indicate that engagement of NKR-P1A by its ligand LLT1 (54, 55) inhibited rather than induced NK cell-mediated lysis (54). Furthermore, the nature of the adaptor molecule associated with NKR-P1A remains undefined. Thus, the role of cPLA2 could not be ascribed to particular cytolytic signaling pathways and to individual NK receptors in human. Our study unambiguously identifies the NKG2D-DAP10 in human CTLs as an immunoreceptor complex that requires cPLA2 activation and AA release as integral components of its cytolytic machinery. In addition, our preliminary data indicate that this finding is not limited to CTLs, because the NKG2D cytolytic pathway in NK cells also involves cPLA2 activation (unpublished data). Interestingly, our data suggest that cPLA2 is not significantly involved in TCR-mediated cytolysis. Future studies will determine whether, more generally, ITAM-signaling receptors mobilizing high levels of calcium mediate granule exocytosis independently of cPLA2. In agreement, NK cell receptors associated with ITAM-bearing adaptor molecules induce high levels of calcium flux (47) and cPLA2-independent cytolysis (56). Importantly, however, even though cPLA2 is not directly involved in TCR-mediated cytolysis, it plays a critical role in the co-stimulation of cytolytic T cell responses. Notably, NKG2D was unsuccessful to induce cPLA2 phosphorylation in resting CD8+TCRalphabeta+ peripheral blood lymphocytes. This finding may explain why NKG2D fails to exert co-stimulatory function in resting noneffector CD8 T cells (57). Together, these observations are in agreement with the general concept, reported by Bryceson et al. (58, 59) that receptors using different adapters and signaling pathways contribute distinctively and synergistically to cytolysis.
###end p 47
###begin p 48
###xml 124 130 120 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7</xref>
###xml 133 135 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 137 139 133 135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib60">60</xref>
###xml 141 143 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib61">61</xref>
###xml 353 359 349 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7</xref>
###xml 362 363 358 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 521 522 517 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 524 526 520 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">62</xref>
###xml 528 530 524 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">63</xref>
###xml 658 660 654 656 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 662 664 658 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib64">64</xref>
###xml 665 667 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib68">68</xref>
###xml 724 726 720 722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib62">62</xref>
###xml 728 730 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib63">63</xref>
###xml 780 782 776 778 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib67">67</xref>
###xml 865 871 861 867 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7</xref>
###xml 1042 1043 1038 1039 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1135 1141 1131 1137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig7">Fig. 7</xref>
###xml 1183 1184 1179 1180 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1244 1246 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib22">22</xref>
###xml 1248 1250 1244 1246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib44">44</xref>
###xml 1252 1254 1248 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib45">45</xref>
###xml 1487 1489 1483 1485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib28">28</xref>
###xml 1792 1794 1788 1790 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib51">51</xref>
###xml 1796 1798 1792 1794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib52">52</xref>
###xml 1827 1829 1823 1825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib69">69</xref>
###xml 1831 1833 1827 1829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib70">70</xref>
###xml 175 180 <span type="species:ncbi:9606">human</span>
###xml 623 628 <span type="species:ncbi:10090">mouse</span>
###xml 633 638 <span type="species:ncbi:9606">human</span>
Studies had identified PLC-gamma2, PI3-K, and Grb2/Vav1 as key upstream signaling molecules of the NKG2D cytolytic pathway (Fig. 7) (33, 60, 61). Our previous analysis of the human NKG2D-DAP10 cytolytic signaling pathway suggested that ERK and JNK, activated through independent pathways, played critical roles in NKG2D- but not TCR-mediated cytolysis (Fig. 7) (6). The role of PI3K in cytolysis is complex and remains incompletely understood; among its potential roles, PI3K is thought to be involved in ERK activation (6, 62, 63). A critical role for Vav in natural killer signaling and cytotoxicity has been reported in mouse and human by several groups (33, 64-68). Vav is thought to play a role similar to that of ERK (62, 63) in cytolysis by promoting granule polarization (67). This study reveals that Vav1 is upstream of JNK in the NKG2D cytolytic pathway (Fig. 7). More importantly, it sheds a new light on the role of the PI3K-ERK and Vav-JNK pathways in NKG2D-mediated cytolysis by showing that ERK and JNK critically regulate cPLA2 activation, which in turn critically regulates NKG2D-mediated degranulation and cytolysis (Fig. 7). Whether AA, which is released upon cPLA2 activation, plays a role in granule exocytosis as fusogen (22, 44, 45) or indirectly through its role in the biosynthesis of eicosanoids remains to be determined. AA serves as a substrate to 5-LO and cyclooxygenase (COX), which drive the leukotriene and prostaglandin synthesis pathways, respectively (28). Interestingly, although NKG2D engagement induces 5-LO and COX activation, only 5-LO is involved in NKG2D-mediated cytolysis (unpublished data). These observations are in agreement with reports suggesting that leukotrienes, but not prostaglandins, play a role in lymphokine-activated killer activity (51, 52) and NK-mediated cytolysis (69, 70).
###end p 48
###begin p 49
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 273 274 273 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 428 430 428 430 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib71">71</xref>
###xml 432 434 432 434 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib72">72</xref>
###xml 555 557 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib73">73</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib71">71</xref>
###xml 781 782 781 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib13">13</xref>
###xml 1063 1064 1061 1062 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 1240 1241 1238 1239 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1267 1268 1265 1266 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1346 1347 1344 1345 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1434 1435 1432 1433 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1496 1498 1494 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib74">74</xref>
###xml 1317 1325 <span type="species:ncbi:9606">patients</span>
Convergent observations suggest that IL-15 and NKG2D may coordinately regulate CTL effector functions and mediate organ-specific immunopathology (for review see reference [15]). For instance, the role of NKG2D as a direct mediator of cytolysis was shown in celiac disease (6). Celiac disease is an inflammatory intestinal disorder with an autoimmune component triggered by dietary gluten in genetically susceptible individuals (71, 72). Although the role of gluten-specific, DQ2- or DQ8-restricted CD4 T cells in the lamina propria was accepted early on (73), the role of IE-CTLs was questioned because no gluten-specific IE-CTLs could be identified (for review see reference [71]). Our finding that IL-15 primed NKG2D in CTLs to kill MIC-expressing enterocytes in celiac disease (6, 13) provided an explanation as to how IE-CTLs could cause intestinal damage and malabsorption, despite their inability to recognize gluten. Licensing by IL-15 was shown to involve up-regulation of NKG2D and DAP-10 expression, and activation of the PI3-K-->ERK signaling pathway (6). We now show that IL-15 is also involved in the activation of JNK. More importantly, we demonstrate that IL-15-mediated licensing of the NKG2D cytolytic pathway requires cPLA2 activation, and that cPLA2 is highly activated in IE-CTLs of active celiac patients. Interestingly, cPLA2 is concomitantly activated in the intestinal epithelial cells. This activation of cPLA2 may be secondary to the activation of enterocytes by IL-15 (74) and/or AA released by IE-CTLs.
###end p 49
###begin p 50
###xml 389 391 389 391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib75">75</xref>
###xml 392 394 392 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib79">79</xref>
###xml 738 740 738 740 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib15">15</xref>
###xml 781 783 781 783 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib80">80</xref>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib84">84</xref>
Finally, our study reveals that NKG2D and IL-15 signaling in effector CTLs causes CTLs to release AA and potentially eicosanoids, such as leukotrienes and prostaglandins. Eicosanoid synthesis by CTLs is supported by our findings that NKG2D induces AA production and activates 5-LO and COX (unpublished data). Interestingly, AA and eicosanoids favor granulocyte recruitment and activation (75-79). These findings establish an unrecognized link between CTLs, NKG2D, IL-15, and inflammation, which may have as of yet unrecognized pathological implications. In particular, it may be relevant in immune-mediated diseases, such as rheumatoid arthritis and celiac disease, where NKG2D and IL-15 play a pathogenic role (for review see reference [15]) and where granulocytes are activated (80-84).
###end p 50
###begin p 51
###xml 169 170 169 170 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 540 542 540 542 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib85">85</xref>
###xml 544 546 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib86">86</xref>
Collectively, our findings invite us to reexamine the role of IL-15 and NKG2D in inflammation and autoimmunity, and develop therapeutic strategies aimed at blocking cPLA2 in diseases associated with dysregulated IL-15 expression and NKG2D activation. Future studies will determine whether 5-LO and COX should also be targeted. Our preliminary observations suggest that 5-LO, but not COX, is involved in NKG2D-mediated immunopathology. In addition, in view of observations suggesting that prostaglandins inhibit NK cell cytolytic responses (85, 86), blocking COX activation may even be deleterious.
###end p 51
###begin title 52
MATERIALS AND METHODS
###end title 52
###begin title 53

###end title 53
###begin title 54
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human subjects.
###end title 54
###begin p 55
###xml 554 555 554 555 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 43 51 <span type="species:ncbi:9606">patients</span>
For immunohistochemical studies, six adult patients with active celiac disease and four control aged-matched individuals undergoing biopsies for functional intestinal disorders of nonceliac origin were studied. Diagnosis of celiac disease was based on detection of antitransglutaminase antibodies, the presence of HLA DQ2 or DQ8, villous atrophy, and clinical and histological response to a gluten-free diet. In addition, IE-CTLs were isolated from surgical specimens of individuals undergoing gastric bypass for morbid obesity, as previously described (6). All subjects gave written informed consent and research was approved by the University of Chicago Institutional Review board.
###end p 55
###begin title 56
CTL isolation and cell culture.
###end title 56
###begin p 57
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 140 141 140 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 144 145 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 148 149 148 149 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 223 225 223 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 431 432 431 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib1">1</xref>
###xml 434 435 434 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib8">8</xref>
###xml 466 467 466 467 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 479 480 472 473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 594 595 587 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 597 599 590 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 981 982 971 972 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 994 995 977 978 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1068 1069 1051 1052 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1221 1223 1204 1206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib31">31</xref>
###xml 1316 1317 1299 1300 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
IE-CTLs were purified from jejunal biopsies and surgical specimens, as previously described (31). Intraepithelial and peripheral blood NKG2D+TCR+CD8+ CTL lines and clones were obtained and cultured as previously described (31). PB-CTL clone #348 and #414 (cultured with 5 U/ml of IL-2) in which NKG2D exerts co-stimulatory cytolytic functions but cannot induce direct cytolysis were obtained and cultured, as previously described (1, 8). Resting peripheral blood CD8+TCRalphabeta+ T lymphocytes were purified and an effector CTL line was generated according to a previously described protocol (6, 31). In brief, peripheral blood lymphocytes were isolated from whole blood of healthy volunteers after Ficoll density gradient centrifugation (GE Healthcare). Cells were stained with anti-CD8beta APC-conjugated mAb (BD) and purified by AutoMACS (Miltenyi Biotec) using anti-APC magnetic beads (Miltenyi Biotec). Purity (>95%) of isolation was confirmed by flow cytometry. Purified CD8+TCRalphabeta+ T cells were divided into two parts. One part was directly used for cPLA2 signal transduction experiments. The other part was used to generate a short-term effector CTL line by allogenic stimulation, as previously described (31), to investigate whether the effector status impacted on the ability of NKG2D to induce cPLA2 phosphorylation.
###end p 57
###begin p 58
###xml 84 85 84 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 97 98 90 91 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 212 213 205 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 268 274 <span type="species:ncbi:10090">murine</span>
MICA-transfected (C1R-MIC) or control vector-transfected (C1R-Neo) C1R cells and CD8+TCRalphabeta+ cytotoxic leukemia TALL-104 cell line (American Type Culture Collection) were cultured, as previously described (6). EL4 (American Type Culture Collection TIB-39) are a murine T lymphoma cell line. MICA-transfected EL4 (EL4-MICA) and control EL4 cells were grown in RPMI 1640 supplemented with 10% FCS, glutamine, antibiotics, and G 418.
###end p 58
###begin title 59
Reagents, antibodies, and recombinant cytokines.
###end title 59
###begin p 60
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 360 361 360 361 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 386 387 386 387 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 685 686 681 682 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 687 691 <span type="species:ncbi:9925">goat</span>
###xml 697 702 <span type="species:ncbi:10090">mouse</span>
###xml 770 775 <span type="species:ncbi:9606">Human</span>
cPLA2 inhibitor AACOCF3, MEK1/2 inhibitor PD98059, and JNK inhibitor SP600125 were obtained from Calbiochem. AA and LA were obtained from Sigma-Aldrich. Anti-CD3 (clone UCHT1, IgG1) and anti-NKG2D mAbs (clone 1D11, IgG1) and isotype-matched control IgG1 were purchased from BD; PE-conjugated anti-NKG2D 1D11 was purchased from eBioscience; and anti-Vav1, -cPLA2, -ERK, -JNK-phospho-cPLA2, -phospho-JNKK1, -phospho-PLCgamma2, -phospho-ERK, and -phospho-JNK antibodies were purchased from Cell Signaling Technology. Antiphosphotyrosine mAb 4G10 was obtained from Millipore. Antiactin mAb was purchased from Sigma-Aldrich. Anti-5-LO mAb was obtained from Fitzgerald Industries Int. F(ab')2 goat anti-mouse antibodies were obtained from Jackson ImmunoResearch Laboratories. Human IL-15 and IL-2 were purchased from BD.
###end p 60
###begin title 61
Plasmids, siRNA, and transfection.
###end title 61
###begin p 62
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib33">33</xref>
###xml 386 388 386 388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib36">36</xref>
###xml 390 392 390 392 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib37">37</xref>
###xml 580 582 580 582 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib35">35</xref>
###xml 589 590 589 590 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1173 1174 1173 1174 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 1182 1183 1182 1183 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 1241 1242 1241 1242 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1319 1320 1319 1320 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 156 160 <span type="species:ncbi:162683">Mayo</span>
Dominant-negative mutant Vav1 plasmid (pcDNA3.flag.h.Vav1-C) that contains only the C-terminal portion of Vav1 was a gift from P. Leibson and D. Billadeau (Mayo Clinic College of Medicine, Rochester, MN,) (33). Dominant-negative MEK1(S218a, S222a, MEK[2A]), and constitutively activated MEK1(MEK[2E]) expression plasmid were gifts from M.R. Rosner (University of Chicago, Chicago, IL) (36, 37). Expression vectors encoding JNKK2-JNK1 (which encodes a constitutively active form of JNK), JNKK2(K149M)-JNK1 (a kinase-deficient mutant), and JNKK2(KM) have been previously described (35). cPLA2, 5-LO, and control synthesized siRNA oligonucleotides were purchased from Santa Cruz Biotechnology, Inc. TALL-104 CTL cells were electroporated with the Amaxa Nucleofector (Amaxa, Inc.), using Amaxa Cell Line nucleofection solution V and program T-20. Cells were cultured for 24-72 h before being used for experiments. For overexpression experiments involving HA-tagged JNKK2-JNK1, HA-tagged JNKK2(KM)-JNK1, or MEK(2E), TALL-104 CTLs were cotransfected with the indicated plasmids and GFP plasmid at a 5:1 ratio. 40 h after transfection, cells were sorted by flow cytometry into GFP+ and GFP- cells with FACSAria (BD) before being analyzed for p-cPLA2, p-JNK, and p-ERK expressions by Western blot. For siRNA experiments, 4 x 106 cells were transfected with 120 pmol siRNA and 30 pmol GFP plasmid. On average, 40% of cells were transfected based on GFP expression. Efficiency and specificity of protein knock-down was assessed by Western blot with the appropriate antibodies.
###end p 62
###begin title 63
Cell signaling.
###end title 63
###begin p 64
###xml 15 16 15 16 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 358 359 346 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 585 586 567 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 588 589 570 571 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 933 937 <span type="species:ncbi:9925">goat</span>
###xml 943 948 <span type="species:ncbi:10090">mouse</span>
###xml 962 968 <span type="species:ncbi:9793">donkey</span>
###xml 974 980 <span type="species:ncbi:9986">rabbit</span>
###xml 1239 1245 <span type="species:ncbi:9986">rabbit</span>
To look at cPLA2, JNK, and ERK phosphorylation, cells were serum-starved for 30 h. To test the effects of kinase inhibitors, cells were preincubated for 30 min at 37degreesC with the indicated inhibitors before stimulation. To cross-link immunoreceptors, cells were incubated for 4 min at 4degreesC with the indicated monoclonal antibody before adding F(ab')2 GAM for the indicated duration at 37degreesC. Cells were lysed for 20 min in ice-cold lysis buffer containing fresh protease and phosphatase inhibitors (50 mM Tris-Hcl [pH 7.5]; 150 mM NaCl; 1% Triton-X100; 1 mM EDTA; 1 mM Na3VO4; 1 mM NaF; and protease inhibitor cocktail tablets). Cellular debris was removed by centrifugation at 15,000 rpm for 20 min at 4degreesC. Total lysates were subjected to SDS-PAGE electrophoresis and transferred to PVDF membranes (Bio-Rad Laboratories). Proteins were then detected by using the indicated antibodies, followed by HRP-conjugated goat anti-mouse (HRP-GAM) or donkey anti-rabbit (HRP-DAR) antibodies (Jackson Immunoresearch Laboratories) using the enhanced chemiluminescence (ECL) kit from GE Healthcare. Tyrosine-phosphorylated Vav1 was revealed by antiphosphotyrosine (4G10) antibody after immunoprecipitation of the cell lysates with rabbit polyclonal anti-Vav1 antibody.
###end p 64
###begin title 65
Cytotoxicity assay.
###end title 65
###begin p 66
###xml 90 91 86 87 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 265 266 261 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 92 97 <span type="species:ncbi:10090">mouse</span>
Chromium release assays were performed as previously described using P815 cells (a Fcgamma+ mouse mastocytoma; American Type Culture Collection), C1R-MICA1, EL4-MICA1, control C1R transfectants, and control EL4 cells at the indicated E:T ratio in triplicate wells (6). For Fc-dependent redirected cytotoxicity, effectors and targets were incubated in the presence of soluble anti-NKG2D or anti-CD3 mAbs at the indicated concentration. Chromium release was measured using a scintillation counter (Packard). Maximum release was determined by the addition of detergent (10% SDS) and spontaneous release ranged from 5-10% of the maximum. The percentage of specific cytotoxicity was calculated using the formula 100 x (cpm experimental - cpm spontaneous)/(cpm maximum - cpm spontaneous). When indicated, effector cells were treated for 30 min before and during the cytotoxic assay with different inhibitors, lipid mediators, or equivalent concentrations of the DMSO or ethanol vehicles.
###end p 66
###begin title 67
AA release assay.
###end title 67
###begin p 68
###xml 2 3 2 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 79 80 75 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 200 201 190 191 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 286 287 276 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 533 534 517 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 663 664 647 648 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 726 727 710 711 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 770 771 754 755 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 786 787 770 771 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 798 799 782 783 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 168 174 <span type="species:ncbi:9913">bovine</span>
###xml 383 389 <span type="species:ncbi:9913">bovine</span>
###xml 472 477 <span type="species:ncbi:10090">mouse</span>
###xml 535 539 <span type="species:ncbi:9925">goat</span>
###xml 545 550 <span type="species:ncbi:10090">mouse</span>
106 cells/ml IE-CTLs, PB-CTLs, and TALL-104 CTLs were labeled with 0.2 microCi 3H AA (specific activity 62.5 Ci/mmol; PerkinElmer) in RPMI 1640 or IMDM with 0.2% fetal bovine serum at 37degreesC 5% CO2 for 1 or 8 h. After labeling, cells were washed at least three times to remove free 3H AA and, when indicated, pretreated with inhibitors or vehicles for 30 min in medium with 0.2% bovine serum albumin (BSA). Cells were then incubated with anti-NKG2D, anti-CD3 mAbs, or mouse IgG1 control at 37degreesC for 4 min followed by F(ab')2 goat anti-mouse IgG for 1 h in medium with 0.2% BSA. Supernatants and cell pellets were separately collected by centrifugation. 3H AA was measured with a scintillation counter. Percentage of 3H AA release was calculated as supernatant 3H/(supernatant 3H + pellet 3H) x 100.
###end p 68
###begin title 69
Flow cytometric analysis.
###end title 69
###begin p 70
For surface staining, cells were incubated with fluorochrome-conjugated antibodies according to standard protocols. Fluorescence was analyzed on a six-color FACSCanto (Becton Dickinson) with quadrants set to score as negative >99% of control Ig-stained cells.
###end p 70
###begin title 71
Measurement of granule release by BLT esterase assay.
###end title 71
###begin p 72
###xml 55 56 55 56 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib6">6</xref>
###xml 276 277 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 250 254 <span type="species:ncbi:9925">goat</span>
###xml 260 265 <span type="species:ncbi:10090">mouse</span>
Granule release was evaluated as previously described (6). In brief, CTLs were suspended in RPMI medium containing 2% FCS, incubated in 96-well with 4 microg/100 microl of anti-NKG2D mAb or isotype control for 4 min, and then stimulated for 4 h with goat anti-mouse IgG F(ab')2 at 37degreesC. Maximum granule release was determined using 1% Triton X-100. The supernatants were evaluated for esterase secretion using a standard N-benzyloxycarbonyl lysine thiobenzyl ester (BLT; Calbiochem). The percentage of BLT esterase activity was calculated using the following equation: (experimental BLT esterase release - spontaneous BLT esterase release)/(maximum BLT esterase release - spontaneous BLT esterase release) x 100.
###end p 72
###begin title 73
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
cPLA2 enzyme activity assay.
###end title 73
###begin p 74
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib87">87</xref>
###xml 227 228 227 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 472 473 464 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
###xml 475 476 467 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
###xml 810 811 786 787 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
cPLA2 activity was assessed in lysates of primary IE-CTL, PB, and IE-CTL lines according to the manufacturer's procedure (Cayman Chemical), as reported (87), using arachidonoyl thio-PC as a synthetic substrate. In brief, 4 x 106 cells were stimulated with anti-NKG2D or isotype control, and the pellets were lysed by three cycles of freeze thawing in lysis buffer (50 mM Hepes, pH 7.4, containing 1 mM EDTA, 1 microg/ml leupeptin, 5 microg/ml aprotinin, 1 mM PMSF, 2 mM Na3VO4, 2.5 mM NaF, and 1 mM DTT). 10 microl sample supernatant and 5 microl assay buffer were well mixed and the reaction was initiated by adding 200 microl substrate solution to the wells. After 1 h incubation at room temperature, 10 microl of DTNB/EGTA was added to each well to stop the reaction. Absorbance was measured at 414 nm. cPLA2 activity was expressed as the percentage of nonstimulated control (absorbance of stimulated cells/absorbance of nonstimulated cells) x 100.
###end p 74
###begin title 75
Immunohistochemistry and image analysis.
###end title 75
###begin p 76
###xml 60 61 60 61 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 273 274 269 270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 244 250 <span type="species:ncbi:9986">rabbit</span>
Immunohistochemical double staining for CD3 and phospho-cPLA2 was performed on 4 microM 10% formalin-fixed paraffin sections using the double staining blocking kit (DAKO). Monoclonal anti-CD3 antibody was used at 1:200 dilution (BioGenex), and rabbit polyclonal anti-p-cPLA2 and isotype antibody were used at 1:50 dilution.
###end p 76
###begin p 77
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib39">39</xref>
###xml 259 261 259 261 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="bib40">40</xref>
###xml 516 517 516 517 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 782 783 782 783 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 870 871 870 871 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+</sup>
###xml 919 925 919 925 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="fig6">Fig. 6</xref>
###xml 1029 1030 1029 1030 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1127 1128 1127 1128 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
To control for evaluation bias inherent to subjective morphological inspection and background staining, automatic image analysis with the pixel and cell/object-based image analysis was performed using ACIS software from Clarient, as previously described (39, 40). For each slide, 5-6 areas were scanned at 200x magnification to yield high-resolution digital images. The ACIS software applies the color-specific thresholds configured by an experienced user-pathologist (MT) to differentiate specific blue phospho-cPLA2 staining within lymphocytes and epithelial cells from the surrounding blue background staining. The same threshold values for specific blue staining were applied to both control and active celiac biopsy sections. The overlay tool was used to highlight phospho-cPLA2-positive areas (defined by blue staining above background) in red color within the CD3+ (brown) intraepithelial lymphocyte population (Fig. 6). From each digital image, at least 100 IE-CTLs were selected and numbered for analysis of phospho-cPLA2 staining. All cells were classified as either double positive or only CD3 positive (phospho-cPLA2 negative). Results obtained by software analysis were compared with cell counts obtained by manual morphological inspection.
###end p 77
###begin title 78
Statistical analysis.
###end title 78
###begin p 79
Mixed effects models were constructed for all bar graphs in the figures. The treatment variable was included as a fixed predictor. Experimental plate was included as a random predictor in the model. The outcome variable (specific lysis) was log transformed after checking normality of the residuals from the mixed model. Tukey-adjusted pairwise comparisons are reported unless otherwise noted. The main effect of treatment was statistically significant for all conditions tested (P < 0.001).
###end p 79
###begin p 80
For analysis of immunohistochemical data, celiac cases were compared with controls using exact Wilcoxon rank sum tests.
###end p 80
###begin title 81
Online supplemental material.
###end title 81
###begin p 82
Fig. S1 shows dose-dependent inhibition by AACOCF3 (CF3) and rescue by AA of NKG2D-mediated cytolysis. Fig. S2 shows the effect of cPLA2 inhibition by AACOCF3 (CF3) on granzyme and perforin expression in IE- and PB-CTLs. Fig. S3 shows that NKG2D stimulation induces perinuclear cPLA2 translocation and cPLA2 activity in IE- and PB-CTLs in a time-dependent manner. Fig. S4 shows that NKG2D and IL-15 induce cPLA2 phosphorylation in effector, but not resting, peripheral blood CTL. Fig. S5 shows that NKG2D induces notably lower levels of calcium release than the TCR in CTLs. A supplemental materials and methods is also provided. Online supplemental material is available at .
###end p 82
###begin title 83
Supplementary Material
###end title 83
###begin title 84
[Supplemental Material Index]
###end title 84
###begin p 85
This paper is dedicated to the memory of Paul J. Leibson who pioneered the field of NK cell signaling. His work, in particular on NKG2D, has been a source of inspiration.
###end p 85
###begin p 86
The authors would also like to thank Jean-Pierre Kinet, Mark Musch, William De Paolo, and Albert Bendelac for critical reading of the manuscript, Daniel D Billadeau for providing the Vav1 dominant-negative construct, Emily Kistner for help with statistical analysis, Ryan Duggan for cell sorting, and Terry Li for help in the execution of the immunohistochemistry studies. We would also like to thank the University of Chicago Celiac Disease Center and the Columbia Presbyterian Hospital Celiac Disease Center.
###end p 86
###begin p 87
The work was supported by RO1 DK063158, RO1 DK58727, A130581 (TS), and University of Chicago DDRCC P30DK42086.
###end p 87
###begin p 88
The authors have no conflicting financial interests.
###end p 88
###begin article-title 89
Activation of NK cells and T cells by NKG2D, a receptor for stress- inducible MICA.
###end article-title 89
###begin article-title 90
###xml 52 55 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
ULBPs, Novel MHC Class I-Related Molecules, Bind to CMV Glycoprotein UL16 and Stimulate NK Cytotoxicity through the NKG2D Receptor.
###end article-title 90
###begin article-title 91
###xml 28 33 <span type="species:ncbi:9606">human</span>
ULBP4 is a novel ligand for human NKG2D.
###end article-title 91
###begin article-title 92
Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
###end article-title 92
###begin article-title 93
Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.
###end article-title 93
###begin article-title 94
Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease.
###end article-title 94
###begin article-title 95
A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease.
###end article-title 95
###begin article-title 96
Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis.
###end article-title 96
###begin article-title 97
###xml 51 55 <span type="species:ncbi:10090">mice</span>
NKG2D blockade prevents autoimmune diabetes in NOD mice.
###end article-title 97
###begin article-title 98
An activating immunoreceptor complex formed by NKG2D and DAP10.
###end article-title 98
###begin article-title 99
###xml 53 58 <span type="species:ncbi:10090">mouse</span>
###xml 68 73 <span type="species:ncbi:9606">human</span>
A Structural basis for the association of DAP12 with mouse, but not human, NKG2D.
###end article-title 99
###begin article-title 100
###xml 24 29 <span type="species:ncbi:9606">human</span>
Comparative analysis of human NK cell activation induced by NKG2D and natural cytotoxicity receptors.
###end article-title 100
###begin article-title 101
NKG2D receptors induced by IL-15 costimulate CD28-negative effector CTL in the tissue microenvironment.
###end article-title 101
###begin article-title 102
Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells.
###end article-title 102
###begin article-title 103
###xml 67 72 <span type="species:ncbi:9606">human</span>
NKG2 receptor-mediated regulation of effector CTL functions in the human tissue microenvironment.
###end article-title 103
###begin article-title 104
Cytosolic phospholipase A2alpha reigns supreme in arthritis and bone resorption.
###end article-title 104
###begin article-title 105
###xml 43 47 <span type="species:ncbi:10090">mice</span>
Cytosolic phospholipase A2 alpha-deficient mice are resistant to experimental autoimmune encephalomyelitis.
###end article-title 105
###begin article-title 106
5-lipoxygenase: cellular biology and molecular pharmacology.
###end article-title 106
###begin article-title 107
###xml 44 49 <span type="species:ncbi:9606">human</span>
Activation of cytosolic phospholipase A2 in human T-lymphocytes involves inhibitor-kappaB and mitogen-activated protein kinases.
###end article-title 107
###begin article-title 108
###xml 43 48 <span type="species:ncbi:9606">human</span>
Implication of three isoforms of PLA(2) in human T-cell proliferation.
###end article-title 108
###begin article-title 109
Deacylation and reacylation of neural membrane glycerophospholipids.
###end article-title 109
###begin article-title 110
Phospholipaise A2 and arachidonic acid-mediated mechanism of neuroexocytosis: a possible target of botidinum neurotoxin A other then SNAP-25.
###end article-title 110
###begin article-title 111
Secretory phospholipase A2 is released from pancreatic beta-cells and stimulates insulin secretion via inhibition of ATP-dependent K+ channels.
###end article-title 111
###begin article-title 112
###xml 97 102 <span type="species:ncbi:10090">mouse</span>
Role of cytosolic phospholipase A2 in the production of lipid mediators and histamine release in mouse bone-marrow-derived mast cells.
###end article-title 112
###begin article-title 113
###xml 67 72 <span type="species:ncbi:9606">human</span>
Mechanisms of nonimmunological histamine and tryptase release from human cutaneous mast cells.
###end article-title 113
###begin article-title 114
The immediate activator of the NADPH oxidase is arachidonate not phosphorylation.
###end article-title 114
###begin article-title 115
###xml 14 19 <span type="species:ncbi:9606">human</span>
Regulation of human eosinophil degranulation and activation by endogenous phospholipase A2.
###end article-title 115
###begin article-title 116
Phospholipase A2 isoforms: a perspective.
###end article-title 116
###begin article-title 117
Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells.
###end article-title 117
###begin article-title 118
Antigen receptors on immature, but not mature, B and T cells are coupled to cytosolic phospholipase A2 activation: expression and activation of cytosolic phospholipase A2 correlate with lymphocyte maturation.
###end article-title 118
###begin article-title 119
###xml 50 55 <span type="species:ncbi:9606">human</span>
TCR specificity dictates CD94/NKG2A expression by human CTL.
###end article-title 119
###begin article-title 120
Rac-1 dependent stimulation of the JNK/SAPK signaling pathway by Vav.
###end article-title 120
###begin article-title 121
###xml 21 26 <span type="species:ncbi:9606">human</span>
NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway.
###end article-title 121
###begin article-title 122
###xml 108 113 <span type="species:ncbi:9606">human</span>
NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells.
###end article-title 122
###begin article-title 123
The absence of NF-kappaB-mediated inhibition of c-Jun N-terminal kinase activation contributes to tumor necrosis factor alpha-induced apoptosis.
###end article-title 123
###begin article-title 124
Raf, but not MEK or ERK, is sufficient for differentiation of hippocampal neuronal cells.
###end article-title 124
###begin article-title 125
Identification of 2 serine residues of MEK-1 that are differentially phosphorylated during activation by raf and MEK kinase.
###end article-title 125
###begin article-title 126
Inhibition of TGF-beta signaling by IL-15: a new role for IL-15 in the loss of immune homeostasis in celiac disease.
###end article-title 126
###begin article-title 127
Association of E-cadherin, matrix metalloproteinases, and tissue inhibitors of metalloproteinases with the progression and metastasis of hepatocellular carcinoma.
###end article-title 127
###begin article-title 128
Immunohistochemistry and quantitative analysis of protein expression.
###end article-title 128
###begin article-title 129
Selective expansion of intraepithelial lymphocytes expressing the HLA-E-specific natural killer receptor CD94 in celiac disease.
###end article-title 129
###begin article-title 130
Fusion pores and fusion machines in Ca2+-triggered exocytosis.
###end article-title 130
###begin article-title 131
Stimulation of exocytosis without a calcium signal.
###end article-title 131
###begin article-title 132
cis-Unsaturated fatty acids induce the fusion of chromaffin granules aggregated by synexin.
###end article-title 132
###begin article-title 133
PLA2 promotes fusion between PMN-specific granules and complex liposomes.
###end article-title 133
###begin article-title 134
###xml 94 97 <span type="species:ncbi:10116">rat</span>
Differential effects of polyunsaturated fatty acids on membrane capacitance and exocytosis in rat pheochromocytoma-12 cells.
###end article-title 134
###begin article-title 135
###xml 27 32 <span type="species:ncbi:9606">human</span>
Differential regulation of human NK cell-mediated cytotoxicity by the tyrosine kinase Itk.
###end article-title 135
###begin article-title 136
###xml 76 81 <span type="species:ncbi:9606">human</span>
Phospholipid methylation and phospholipase A2 activation in cytotoxicity by human natural killer cells.
###end article-title 136
###begin article-title 137
###xml 73 78 <span type="species:ncbi:9606">human</span>
Second messenger function of arachidonic acid lipoxygenation products in human natural killer cell lysis?
###end article-title 137
###begin article-title 138
###xml 77 82 <span type="species:ncbi:9606">human</span>
Assessment of a role for phospholipase A2 and arachidonic acid metabolism in human lymphocyte natural cytotoxicity.
###end article-title 138
###begin article-title 139
###xml 14 19 <span type="species:ncbi:9606">human</span>
Regulation of human natural killing. IV. Role of lipoxygenase in regulation of natural killing activity.
###end article-title 139
###begin article-title 140
Reversible inhibition of lymphokine-activated killer cell activity by lipoxygenase-pathway inhibitors.
###end article-title 140
###begin article-title 141
###xml 58 61 <span type="species:ncbi:10116">rat</span>
NKR-P1A stimulation of arachidonate-generating enzymes in rat NK cells is associated with granule release and cytotoxic activity.
###end article-title 141
###begin article-title 142
Cutting edge: lectin-like transcript 1 is a ligand for the CD161 receptor.
###end article-title 142
###begin article-title 143
###xml 70 75 <span type="species:ncbi:9606">human</span>
Cutting edge: lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor.
###end article-title 143
###begin article-title 144
###xml 146 151 <span type="species:ncbi:9606">human</span>
CD16 cross-linking induces both secretory and extracellular signal-regulated kinase (ERK)-dependent cytosolic phospholipase A2 (PLA2) activity in human natural killer cells: involvement of ERK, but not PLA2, in CD16-triggered granule exocytosis.
###end article-title 144
###begin article-title 145
###xml 100 105 <span type="species:ncbi:9606">human</span>
###xml 110 115 <span type="species:ncbi:10090">mouse</span>
Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells.
###end article-title 145
###begin article-title 146
Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells.
###end article-title 146
###begin article-title 147
Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion.
###end article-title 147
###begin article-title 148
NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes.
###end article-title 148
###begin article-title 149
###xml 74 79 <span type="species:ncbi:9606">human</span>
The isoforms of phospholipase C-gamma are differentially used by distinct human NK activating receptors.
###end article-title 149
###begin article-title 150
Pivotal role of phosphoinositide-3 kinase in regulation of cytotoxicity in natural killer cells.
###end article-title 150
###begin article-title 151
Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity.
###end article-title 151
###begin article-title 152
Differential requirements for Vav proteins in DAP10- and ITAM-mediated NK cell cytotoxicity.
###end article-title 152
###begin article-title 153
Vav-1 regulates NK T cell development and NK cell cytotoxicity.
###end article-title 153
###begin article-title 154
Role for the Rac1 exchange factor Vav in the signaling pathways leading to NK cell cytotoxicity.
###end article-title 154
###begin article-title 155
Vav1 controls DAP10-mediated natural cytotoxicity by regulating actin and microtubule dynamics.
###end article-title 155
###begin article-title 156
Functional dichotomy in natural killer cell signaling: Vav1-dependent and -independent mechanisms.
###end article-title 156
###begin article-title 157
###xml 16 21 <span type="species:ncbi:9606">human</span>
Augmentation of human natural cytotoxic cell activity by leukotriene B4 mediated by enhanced effector-target cell binding and increased lytic efficiency.
###end article-title 157
###begin article-title 158
###xml 40 45 <span type="species:ncbi:9606">human</span>
Products of the lipoxygenase pathway in human natural killer cell cytotoxicity.
###end article-title 158
###begin article-title 159
Coeliac disease.
###end article-title 159
###begin article-title 160
Is celiac disease an autoimmune disorder?
###end article-title 160
###begin article-title 161
Coeliac disease: dissecting a complex inflammatory disorder.
###end article-title 161
###begin article-title 162
Intestinal epithelial cells both express and respond to interleukin 15.
###end article-title 162
###begin article-title 163
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sub>
A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis.
###end article-title 163
###begin article-title 164
###xml 68 73 <span type="species:ncbi:9606">human</span>
Activation of NADPH oxidase-related proton and electron currents in human eosinophils by arachidonic acid.
###end article-title 164
###begin article-title 165
Lipid mediator networks and leukocyte transmigration.
###end article-title 165
###begin article-title 166
Effects of arachidonic acid analogs on FcepsilonRI-mediated activation of mast cells.
###end article-title 166
###begin article-title 167
###xml 14 19 <span type="species:ncbi:9606">human</span>
Regulation of human leukocyte function by lipoxygenase products of arachidonic acid.
###end article-title 167
###begin article-title 168
Neutrophil-derived cytokines: potential therapeutic targets in inflammation.
###end article-title 168
###begin article-title 169
Neutrophil-derived leukotriene B4 is required for inflammatory arthritis.
###end article-title 169
###begin article-title 170
Activated eosinophils in coeliac disease.
###end article-title 170
###begin article-title 171
###xml 60 68 <span type="species:ncbi:9606">patients</span>
Neutrophil and eosinophil involvement of the small bowel in patients with celiac disease and Crohn's disease: studies on the secretion rate and immunohistochemical localization of granulocyte granule constituents.
###end article-title 171
###begin article-title 172
###xml 73 81 <span type="species:ncbi:9606">patients</span>
Mast cell degranulation after a single dose of gliadin in the jejunum of patients with coeliac disease.
###end article-title 172
###begin article-title 173
Target-effector interaction in the natural killer cell system. IV. Modulation by cyclic nucleotides.
###end article-title 173
###begin article-title 174
###xml 18 23 <span type="species:ncbi:9606">human</span>
The modulation of human natural killer cell activity by prostaglandins.
###end article-title 174
###begin article-title 175
###xml 118 123 <span type="species:ncbi:10090">mouse</span>
Prostaglandin E2 and microsomal prostaglandin E synthase-2 expression are decreased in the cyclooxygenase-2-deficient mouse brain despite compensatory induction of cyclooxygenase-1 and Ca2+-dependent phospholipase A2.
###end article-title 175
###begin article-title 176
A deficiency in Drak2 results in a T cell hypersensitivity and an unexpected resistance to autoimmunity.
###end article-title 176
###begin p 177
###xml 109 110 109 110 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
Abbreviations used: AA, arachidonic acid; BLT, benzyloxycarbonyl lysine thiobenzyl; COX, cyclooxygenase; cPLA2, cytosolic phospholipase A2; ERK, extracellular signal-regulated kinase; IE-CTL, intraepithelial CTL; ITAM, immunoreceptor tyrosine-based activation motifs; JNK, c-Jun N-terminal kinase; LA, linoleic acid; MIC, MHC class I-related chain; PI3-K, phosphatidylinositol 3-kinase; PB-CTL, peripheral blood CTL; siRNA, small interfering RNA; ULPB, UL-16-binding protein.
###end p 177

